U.S. Healthtech Stock News

If you are wondering whether Donaldson Company at around $92 is still worth considering after its strong run, or if the easy money has already been made, you are not alone and that is exactly what we are going to unpack. The stock is up 5.2% over the last week, 4.9% over the past month, and 36.9% year to date, building on multi year gains of 28.8% over 1 year, 61.3% over 3 years, and 75.6% over 5 years. Recent moves have been supported by steady demand for its filtration solutions across...

Dave & Buster's Entertainment (PLAY) has just posted another quarter of solid headline numbers, with Q2 2026 revenue of $557.4 million and basic EPS of $0.33, alongside net income of $11.4 million. The company has seen revenue move from $453 million in Q3 2025 to $534.5 million in Q4 2025, then to $567.7 million in Q1 2026 and $557.4 million in Q2 2026, while EPS swung from a loss of $0.84 in Q3 2025 to positive readings of $0.25, $0.63, and $0.33 over the subsequent quarters. With analysts...

BlackLine (BL) just switched on a new locally hosted cloud region in Saudi Arabia, a calculated move that taps into the Kingdom’s modernization push while satisfying tight data residency and cybersecurity rules. See our latest analysis for BlackLine. That Saudi expansion comes as BlackLine’s 1 month share price return of 7.18% and 3 month gain of 5.97% hint at improving sentiment, even though its 1 year total shareholder return of negative 9.74% shows the longer term picture is still one of...

Apple recently announced a major leadership reshuffle, including the upcoming retirement of general counsel Kate Adams and environment chief Lisa Jackson, and the 2026 arrival of former Meta chief legal officer Jennifer Newstead to lead a newly combined Legal and Government Affairs organization. Alongside these changes, the planned retirement of AI head John Giannandrea and Apple’s wider succession planning highlight how the company is reorganizing senior talent to support its next phase of...

DexCom (DXCM) just rolled out Dexcom Academy, a tailored learning platform for healthcare professionals that could quietly reshape how its continuous glucose monitors are used day to day and, in turn, how investors view the stock. See our latest analysis for DexCom. That launch lands at an interesting moment, with the share price at $67.55 and a 30 day share price return of 23.18% suggesting short term momentum is rebuilding, even as the 1 year total shareholder return of negative 16.06%...

On December 8, 2025, The Macerich Company reported at the Nareit REITWorld conference in Dallas that it had achieved record leasing activity of 3.2 million square feet by the third quarter and completed US$1.20 billion in mall asset sales, alongside opening more than 300 new stores including luxury and international brands. This combination of robust leasing performance and sizable asset sales highlights how Macerich is both filling space with higher-quality tenants and actively reshaping...

Earlier this month, KBRA assigned preliminary ratings to 10 classes of mortgage-backed notes from New Residential Mortgage Loan Trust 2025-NQM7, a non-prime RMBS deal sponsored by Rithm Capital and backed mainly by loans originated by NewRez LLC and Champions Funding, LLC. This latest non-prime securitization highlights Rithm’s ongoing use of capital markets to fund and recycle mortgage risk across its broader real estate credit platform. We’ll now consider how Rithm’s new non-prime RMBS...

If you are wondering whether WisdomTree is still a smart buy at around $11.69, you are not alone. This stock sits at the crossroads of growth, income, and structural change in asset management. After a 4.7% gain over the last week and a strong 15.6% return year to date, the stock has cooled slightly in the last month with a -0.3% move, while still sitting on hefty 3 year and 5 year gains of 125.2% and 162.2% respectively. Those moves have come as WisdomTree has leaned further into thematic...

Hasbro recently reported quarterly revenues of US$1.39 billion, an 8.3% year-on-year increase that surpassed analyst expectations by 3.2%, underscoring the current strength of its core brands and Playing to Win plan. These results were the strongest within its peer group for both revenue growth and analyst estimate beats, highlighting how Hasbro’s operational execution is currently outpacing many competitors in the sector. We’ll now examine how Hasbro’s recent earnings beat, reflecting...

In recent days, L3Harris Technologies has been highlighted as a key player in the U.S. push to accelerate weapons production, as government leaders move to overhaul the defense acquisition system and defense tech firms increase their share of Pentagon contracts. Comments from L3Harris CEO Chris Kubasik about combining the strengths of established contractors and newer defense tech entrants underscore the company’s central role in shaping future U.S. defense capabilities and industry...

The launch of SiTime (SITM) Endura Super TCXO is a meaningful step into high stakes position, navigation, and timing markets, putting ultra stable, spoof resistant timing at the center of the stock story. See our latest analysis for SiTime. Investors seem to be warming to that story, with the share price up 14.0 percent over the past month and a powerful 63.9 percent year to date share price return at 366.49 dollars, building on a 40.4 percent one year total shareholder return. If SiTime has...

Herbalife (HLF) is back in the spotlight after investors reacted to another weak update on sales volumes and earnings per share, which pushed the stock lower as the market refocused on the company’s underlying growth problem. See our latest analysis for Herbalife. Despite the latest pullback on weak volumes and EPS, Herbalife’s share price has climbed to $12.57 and delivered a strong year to date share price return. However, the five year total shareholder return remains deeply negative,...

In December 2025, Ligand Pharmaceuticals issued 2026 guidance calling for total revenue of US$245 million to US$285 million, including US$200 million to US$225 million in royalty revenue, US$35 million to US$40 million in Captisol sales, and US$10 million to US$20 million in contract revenue. The company also raised its 5‑year royalty receipt outlook, highlighting products such as Filspari, Ohtuvayre, and Zelsuvmi and outlining plans to deploy up to US$1.00 billion in capital to support...

Agios Pharmaceuticals (AGIO) is back in focus after the FDA missed its December 7 decision date on the mitapivat thalassemia sNDA, leaving the filing under active review and investors recalibrating timing expectations. See our latest analysis for Agios Pharmaceuticals. The missed PDUFA date seems to have cooled near term enthusiasm, with a roughly 35 percent 1 month share price return decline and a 1 year total shareholder return of about negative 38 percent. This signals fading momentum...

Hello Group (MOMO) just posted softer third quarter numbers, with both revenue and net income slipping year over year. That earnings dip is likely what nudged the stock and investor sentiment today. See our latest analysis for Hello Group. At a share price of $6.98, Hello Group’s 1 year total shareholder return of around negative 5 percent and weaker 90 day share price return suggest momentum has been fading as investors reassess the earnings outlook. If this earnings wobble has you...

If you are wondering whether Goldman Sachs Group is still worth considering after its huge run, or if you would just be paying up for past success, this article will walk through what the numbers are really saying about its valuation. Goldman Sachs shares recently closed at $876.58, after climbing 4.8% over the last week, 10.0% over the last month, and 52.5% year to date, adding to 50.9% over the past year and 304.9% over five years, which has clearly reset investor expectations. Behind...

NiSource (NI) has been quietly grinding higher this year, and its recent pullback after a strong run has some investors asking whether this regulated utility is offering a reasonable entry point. See our latest analysis for NiSource. At around $41.44, NiSource’s recent pullback follows a strong year to date share price return, with the 1 year total shareholder return near 16 percent and the 5 year total shareholder return comfortably more than doubling investors’ money. This suggests that...

ONE Gas (OGS) has been quietly slipping over the past week and month, even though its year to date and 1 year returns are still comfortably positive. That disconnect is worth unpacking. See our latest analysis for ONE Gas. With the share price now around $77.64, the recent 7 day and 30 day share price declines sit in sharp contrast to a double digit year to date share price return and solid 1 year total shareholder return. This suggests momentum has cooled, but the longer term trend remains...

Earlier this month, Corpay, Inc. confirmed that Mastercard has completed a US$300 million minority investment in Corpay’s cross-border business and signed a new commercial partnership to offer Corpay’s services to Mastercard’s financial institution clients, while Corpay is also broadening its use of Mastercard Move for real-time payments in more countries. This deepened relationship with Mastercard could meaningfully expand Corpay’s distribution reach in cross-border payments at a time when...

Radware (RDWR) is stepping deeper into AI security, launching its LLM Firewall to shield generative AI workflows from prompt attacks and data leaks, while extending its cloud protection footprint in Japan through Hitachi Solutions. See our latest analysis for Radware. Those AI focused launches come as Radware’s $24.12 share price has delivered an 8.11% year to date share price return and a 2.38% one year total shareholder return, suggesting improving sentiment but not yet runaway momentum. If...

In early December 2025, Amneal Pharmaceuticals announced that the FDA had approved its epinephrine injection USP and multiple new complex generics, including cyclosporine ophthalmic emulsion, albuterol sulfate inhalation aerosol, and an extended-release Parkinson’s therapy, CREXONT. This cluster of approvals opens access to U.S. markets worth billions of dollars in aggregate annual branded sales, potentially reshaping Amneal’s product mix toward higher-value sterile injectables, respiratory,...

Hamilton Insurance Group recently reported a very large year-on-year revenue increase in its third quarter, beating analyst expectations for both earnings and revenue while benefiting from improved combined ratios amid unusually low catastrophe losses. Beyond headline growth, the company’s hedge fund investment performance and ongoing share buybacks appear to be reinforcing its capital position and earnings power, supporting confidence in its specialty insurance and reinsurance...

New Oriental Education & Technology Group Inc. was recently removed from the Hang Seng China Enterprises Index, reflecting a reshuffle in one of Hong Kong’s key benchmarks for mainland-linked companies. This index removal can influence institutional fund flows and sentiment, as some investors track or benchmark against the Hang Seng China Enterprises Index when allocating capital. We’ll now explore how New Oriental’s removal from the Hang Seng China Enterprises Index could influence its...

BETA Technologies (BETA) shares climbed about 2% today, extending a roughly 9% gain over the past week, as investors weigh rapid revenue growth against ongoing losses and a weaker year-to-date performance. See our latest analysis for BETA Technologies. Despite the latest close at $31.02 and a solid 7 day share price return of 9.34%, the year to date share price return of negative 13.83% shows that, for now, this bounce looks more like early rebuilding of momentum than a full trend...